DURECT Corp (DRRX.OQ)

DRRX.OQ

About

Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company’s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.24
Market Cap (Mil.):	$92.56
Shares Outstanding (Mil.):	101.89
Dividend:	--
Yield (%):	--

Financials

	DRRX.OQ	Industry	Sector
P/E (TTM):	4.85	51.10	35.42
EPS (TTM):	0.19	--	--
ROI:	44.19	1.74	18.86
ROE:	81.39	2.98	19.73

Latest News about DRRX.OQ

Pain Therapeutics, Durect shares soar on Pfizer's Remoxy comments

- Shares of Pain Therapeutics Inc and Durect Corp rose more than 40 percent after partner Pfizer Inc said it is in talks with U.S. health regulators to find a way forward on the companies' painkiller, Remoxy.

30 Apr 2013

» More DRRX.OQ News

Competitors

	Price	Change
Pfizer Inc. (PFE.N)	$29.11	-0.19
Novartis AG (NOVN.VX)	CHF71.70	+0.25
AstraZeneca plc (AZN.L)	3,431.50p	+5.00
Medtronic, Inc. (MDT.N)	$51.46	-0.07
Shire PLC (SHP.L)	2,135.00p	+1.00
Shire PLC (3159084.L)	--	--
Endo Health Solutions Inc (ENDP.OQ)	$34.28	+0.66
Nektar Therapeutics (NKTR.OQ)	$9.31	+0.07
Cadence Pharmaceuticals, Inc. (CADX.OQ)	$6.87	-0.31
NeurogesX, Inc (NGSX.PK)	$0.01	0.00

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - DURECT CORPORATION (DRRX-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
ValuEngine Detailed Valuation Report for DRRX Provider: ValuEngine, Inc.	$127.00 Buy
DURECT CP (DRRX) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
DURECT Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
DURECT Corporation (DRRX) - Financial and Strategic SWOT Analysis Review Provider: GlobalData	$125.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.